BioSpace News Archive

Sera Prognostics Inc. today announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth to allow more timely intervention.

Caldera Medical Announces FDA Clearance for New Desara ® TVez for Stress Urinary Incontinence.

IVERIC bio, Inc. reported that on December 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, is launching new Research Nursing and Phlebotomy services.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the appointment of Constantine Chinoporos as Chief Business Officer and a member of the Albireo Enterprise Leadership Team.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced new preclinical data from its exoVACC™ exosome-based vaccine platform.

Mindset Pharma Inc. today announced that it will participate in Stifel GMP’s The Future of Healthcare Conference to be held virtually on Wednesday, December 8, 2021.

Dyne Therapeutics, Inc. (Nasdaq: DYN), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

BIOREM Inc. is pleased to announce that it has completed the transaction to purchase for cancellation 23,434,121 common shares at $0.5256 per common share from TPFG Environment Investment Limited.